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new triple therapy warrant evaluation of these new treatment
options for all coinfected patients.
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epatitis C: Asia-Paciﬁc perspective
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ospital, Hat Yai, Thailand
Chronic hepatitis C is one of the leading causes of cirrhosis
ndhepatocellular carcinoma. There are approximately 170million
eople chronically infectedwithhepatitis C virus (HCV)worldwide.
mong chronic hepatitis C patients, over 100 million patients live
n the Asia Paciﬁc region. The prevalence of HCV among adults in
sia Paciﬁc ranges from 0.8% to 9.6%. The major risks of infection
re receiving a blood transfusion prior to universal donor screening
or anti-HCV, shared needle including intravenous drug use, tat-
ooing and unsafe injections. A study in India reported over 60%
f the patients had cirrhosis at their ﬁrst diagnosis. HCV geno-
ype 1 in Asians has a better sustained virological response with
egylated interferon /ribavirin treatment than in Caucasians (70%
s 50%). The better response in Asians is due to a more favorable
ost genome in Asians. Over 70% of the Asian populations have
ost IL28Bgenotype CC which is associated with better treatment
esponse . Currently, responseguided therapywithpegylated inter-
eron /ribavirin is a standard HCV treatment in Asia Paciﬁc. The
ates of hepatitis C and hepatitis B (HCV/HBV) virus co-infections
re 0.1% to 4% in Asia. PatientswithHCV/HBV co-infection are asso-
iated with poorer long-term outcomes than with monoinfection.
CV/HBV co-infection responds to pegylated interferon/ribavirin
reatment as well as HCV monoinfection (72% vs 77% in genotype
and 83% vs 84% in genotype 2/3). Due to a higher prevalence of
enotype 2, 3 in someAsian counties and higher sustained virologi-
al response in genotype 1 in Asians, treatment of chronic hepatitis
may be even more cost-effective in this region.
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reatment of hepatitis C in 2012
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Signiﬁcant progress has been made in treatment of hepatitis
infection since the virus was discovered over 2 decades ago.
lthough interferon-alpha continues to be themainstay of therapy,
seofpegylated interferons, bothalpha-2aandalpha-2b, combined
ith ribavirin signiﬁcantly improved the treatment outcomes, par-icularly for genotypes 2 and 3. Furthermore, after introduction of
he two NS3/4 protease inhibitors, telaprevir and boceprevir, the
reatment outlook for genotype1has also become signiﬁcantly bet-nfectious Diseases 16S (2012) e2–e157
ter. Clinical trials have shown improved sustained viral responses
(SVRs) in patients with HCV genotype 1 when they received either
telaprevir or boceprevir in addition to a pegylated interferon-
alpha and ribavirin. With both triple drug regimens, higher rates
of SVRs can be achieved in patients who are treatment naïve, non-
responders as well as patients with relapses. However, use of triple
drug regimen is also associatedwithhigher ratesof sideeffects. This
presentation will provide an overview and update on treatment of
hepatitis C infection.
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Management of hepatitis C in HIV-coinfected patients
J. Rockstroh
Medical University Clinic, Bonn-Venusberg, Germany
With the development of effective therapies against HIV,
chronic HCV infection has become a major cause of morbidity
and mortality among patients harboring both infections. There-
fore, ﬁbrosis stage assessment and consideration of HCV treatment
options is of utmost importance in this particular patient group.
Over the last years, treatment with pegylated interferon (IFN) plus
ribavirin (RBV) has been recommended for co-infected patients
who are at the greatest risk for liver disease progression, how-
ever, despite acceptable response rates for HCV genotype 2 and
3 patients, the effectiveness of HCV treatment in the widespread
genotype 1 and 4 patients has been disappointing. Therefore, the
development of direct acting antivirals for treatment of HCV has
beeneagerlyawaited tohopefully improveHCVtreatmentoutcome
in coinfected individuals. The ﬁrst SVR12 week results from pilot
trials with either boceprevir or telaprevir in HCV treatment-naive
GT 1 patients with HIV coinfection with over 30% higher cure rates
thanunder traditional PEG-IFN/RBV therapyhave started to change
the gold standard of treating hepatitis C. Nevertheless, numerous
challenges remain including choice of patients to treat, potential
for drug-drug interactions and overlapping toxicities between HIV
and HCV therapy. Although treatment of the HIV/HCV coinfected
patients remains difﬁcult and contains considerable clinical and
economic challenges, drastically improved cure rates of HCV under
